جمالی, فرزانه ، شهرامی, بیتا ، نجم الدین, فرهاد ، حدادی, آذر ، شریف زاده, محمد ، عرب زاده, امیر احمد ، مجتهدزاده, مجتبی (1400) تغییرات سطح لیپوکسین 4 به دنبال درمان زودهنگام بیمارستانی بیماران مبتلا به کووید-19. در: 6th International Conference on Prevention & Infection Control (ICPIC), 14-17 September 2021, Geneva.
متن کامل
|
متنی
- نسخه چاپ شده
750kB |
آدرس اینترنتی رسمی : https://conference.icpic.com/
عنوان انگليسی
Changes of lipoxina4 levels following early hospital management of patients with COVID‑19
خلاصه انگلیسی
Introduction: LipoxinA4 (LXA4) is an anti-inflammatory biomarker that participates in the active process of inflammation resolution which is suggested to be beneficial in infectious and inflammatory diseases like the coronavirus disease 2019 (COVID-19). Objectives: This study aimed to determine early changes of LXA4 levels in the hospitalized patients with confirmed COVID-19 following the clinical management as well as its correlation with common used inflammatory markers, including Erythrocyte Sedimentation Rate (ESR), C-reactive protein (CRP), and ferritin. Methods: Thirty-one adult hospitalized patients with the non-severe COVID-19 were included. LXA4, ESR, and CRP serum levels were collected on the first day of hospitalization, and LXA4 levels were measured 48–72 h later as well. Moreover, the maximum serum ferritin level during the five days of following patients was collected. Results: The mean age of patients was 61.9 ±17 years, and the male to female ratio was 18:13. LXA4 levels were significantly increased at 48–72 h compared to the baseline concentrations (9.9 ±0.7 vs. 21.7 ±15.1 ng/L; P < 0.05). The mean baseline concentrations of CRP and ESR and the mean maximum concentration of ferritin were 74.7 ±57.3 mg/L, 55.7 ±34.4 mm/h, and 568.7 ± 530 ng/mL, respectively. Besides, CRP and ESR levels at the time of admission and maximum ferritin levels during the hospitalization were positively correlated to an increase of LXA4 levels (R = 0.499, 0.535, 0.398; P = 0.007, 0.005, 0.043, respectively). Conclusion: LXA4 may be a valuable marker to assess the treatment response compared to ESR, CRP, and ferritin in hospitalized patients with COVID-19. Furthermore, LXA4 could be considered a potential treatment option in inflammatory conditions. Further studies are necessary to clarify LXA4 role in COVID-19 pathogenesis, as well as the balance between such pro-resolving mediators and inflammatory parameters.
نوع سند : | موضوع کنفرانس یا کارگاه (سخنرانی ) |
---|---|
زبان سند : | انگلیسی |
نویسنده اول : | فرزانه جمالی |
نویسنده : | بیتا شهرامی |
نویسنده : | فرهاد نجم الدین |
نویسنده : | آذر حدادی |
نویسنده : | محمد شریف زاده |
نویسنده مسئول : | امیر احمد عرب زاده |
نویسنده : | مجتبی مجتهدزاده |
ضریب تاثیر و نمایه مجلات: | IF: 4.887 Indexed in: ISI, PubMed/Medline, Scopus, Embase, DOAJ |
کلیدواژه ها (انگلیسی): | , lipoxina4, hospital management patients, COVID‑19 |
موضوعات : | WO جراحی |
بخش های دانشگاهی : | دانشكده پزشكي > گروه جراحی |
کد شناسایی : | 14868 |
ارائه شده توسط : | دکتر بیتا شهباززادگان |
ارائه شده در تاریخ : | 17 آبان 1400 07:43 |
آخرین تغییر : | 17 آبان 1400 07:43 |
فقط پرسنل کتابخانه صفحه کنترل اسناد